ICON Public Limited (NASDAQ:ICLR) – Investment analysts at William Blair upped their Q2 2021 earnings per share estimates for shares of ICON Public in a research report issued on Sunday, May 2nd. William Blair analyst J. Kreger now forecasts that the medical research company will post earnings of $2.11 per share for the quarter, up from their prior estimate of $2.00. William Blair also issued estimates for ICON Public’s Q3 2021 earnings at $2.17 EPS, FY2021 earnings at $8.63 EPS, FY2022 earnings at $9.71 EPS and FY2023 earnings at $10.96 EPS.
Several other equities analysts have also recently commented on ICLR. Barclays initiated coverage on shares of ICON Public in a research note on Monday, March 8th. They set an “equal weight” rating and a $200.00 target price for the company. Credit Suisse Group upped their price target on ICON Public from $240.00 to $245.00 and gave the company an “outperform” rating in a report on Thursday, April 29th. UBS Group upgraded ICON Public from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $207.00 to $232.00 in a research report on Monday, March 8th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of ICON Public from $179.00 to $208.00 and gave the company a “hold” rating in a report on Wednesday, March 3rd. Finally, Truist raised shares of ICON Public from a “hold” rating to a “buy” rating and set a $280.00 price objective for the company in a report on Friday, February 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. ICON Public presently has an average rating of “Buy” and an average target price of $232.60.
ICON Public (NASDAQ:ICLR) last announced its earnings results on Tuesday, April 27th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.97 by $0.09. ICON Public had a return on equity of 21.42% and a net margin of 11.95%.
Several institutional investors and hedge funds have recently made changes to their positions in ICLR. Kornitzer Capital Management Inc. KS raised its position in ICON Public by 36.3% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 115,506 shares of the medical research company’s stock valued at $22,682,000 after purchasing an additional 30,740 shares during the last quarter. Todd Asset Management LLC lifted its position in ICON Public by 18.6% during the 4th quarter. Todd Asset Management LLC now owns 103,487 shares of the medical research company’s stock worth $20,177,000 after buying an additional 16,225 shares in the last quarter. FDx Advisors Inc. lifted its position in ICON Public by 51.6% during the 1st quarter. FDx Advisors Inc. now owns 14,849 shares of the medical research company’s stock worth $2,916,000 after buying an additional 5,057 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in ICON Public by 23.7% during the 4th quarter. Handelsbanken Fonder AB now owns 18,430 shares of the medical research company’s stock worth $3,593,000 after acquiring an additional 3,530 shares during the last quarter. Finally, Fayez Sarofim & Co increased its position in ICON Public by 54.4% in the 4th quarter. Fayez Sarofim & Co now owns 3,180 shares of the medical research company’s stock valued at $620,000 after acquiring an additional 1,120 shares in the last quarter. 81.70% of the stock is currently owned by institutional investors and hedge funds.
ICON Public Company Profile
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development.
Featured Article: What is Cost of Debt?
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.